Cytokine regulation of prethymic T-lymphoid progenitor-cell proliferation and/or differentiation has not been well-defined, although much is known of cytokine regulation of hemopoietic stem-and progenitor-cell development. Here we use a recently identified hemopoietic growth factor, stem-cell factor (SCF) (a form of the c-kit ligand), and a transplant model of thymocyte regeneration to assess the effect of SCF on the in vivo generation of prethymic, thymocyte progenitor-cell activity. We show that 164 recombinant rat SCF (rrSCF administered to weanling rats selectively induces an increase in thymocyte progenitor activity in the spleens of treated rats as compared to rats treated with vehicle, polyethylene glycol (PEG)-conjugated rat albumin, or recombinant human granulocyte colony-stimulating factor (rhG-CSF). These data demonstrate that administration of SCF in vivo affects extrathymic-origin thymocyte regenerating cells and may influence, directly or indirectly, early prethymic stages of Tcell lymphopoiesis in addition to its known effect on early stages of myelopoiesis and erythropoiesis.
INTRODUCTION
Hemopoietic stem and progenitor cells play a central role in the development of all blood-cell lineages (Spangrude et al., 1991) . During the past 10 years, much has been discerned concerning the mechanisms by which hemopoietic stem-and progenitor-cell development is regulated, particularly regarding the regulatory roles of cytokines in myeloid lineage development (Clark and Kamen, 1987) . Less information has been forthcoming about the possible role(s) of cytokines in regulation of lymphoid stem-or progenitor-cell development (Palacios and Pelkonen, 1988) . Recently, a glycoprotein was isolated and identified as a ligand for the tyrosine-kinase receptor c-kit and has been variously termed c-kit-ligand (Huang et al., 1990) , mast cell-growth factor , stem-cell factor , and steel factor (Matsui et al., 1991) .
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The gene for the c-kit ligand has been cloned and the recombinant protein expressed in soluble form (Anderson et al., 1990; Huang et al., 1990; Martin et al., 1990; Langley et al., 1992) .
Numerous in vitro studies have documented that rrSCF164, one form of the c-kit ligand, affects the development of a multitude of myelopoietic (Andrews et al., 1990; Migliaccio et al., 1991) , erythropoietic (McNiece et al., 1991a) , and certain B-lymphoid progenitor cells (McNiece et al., 1991b; Billips et al., 1992) . Moreover, recent studies have shown that SCF administered in vivo causes an increase in spleen-and marrowderived spleen colony-forming units (CFU-S) in Steel-Dickie (S1/S1d) anemic mice (Bodine et al., 1992) . However, little is known of the effect that in vivo administration of SCF may have on lymphopoiesis, particularly its possible effect on early T-cell progenitor development.
In the present study, we have administered rrSCF 164 to rats and evaluated its capability to influence the development of cells able to repopulate the thymus in an irradiation-depen-dent model of thymocyte regeneration (Greiner et al., 1984) . We document that rrSCF 164 causes an increase in spleen cells that can repopulate the thymus of adoptive recipients. These results demonstrate that SCF can affect the development of extrathymic-origin stem/progenitor cells able to reconstitute the thymus in addition to its known effect on myeloid (Andrews et al., 1990; Migliaccio et al., 1991) , erythroid (McNiece et al., 1991a) , and B-lymphoid progenitor cells (McNiece et al., 1991b; Billips et al., 1992 (Andrews et al., 1990; McNiece et al., 1991a McNiece et al., , 1991b Billips et al., 1992; Bodine et al., 1992 sent on all thymocytes) alloantigen disparate recipients (Hale et al., 1987; Sunderland et al., 1979; Thomas et al., 1985 (Greiner et al., 1984 (Greiner et al., 1984) , thymus regeneration resulting from bone marrow cells was not proportiqnal to transplant cell doses when assayed 27 days posttransplantation (Table  3) (Table 3) .
Recipients of spleen cells from rrSCF164-treated rats had greater thymus regeneration than recipients of spleen cells from vehicle-treated rats, but this result was most evident after 27 to 28 days posttransplantation. Recipients of spleen cells from rrSCF164-treated rats analyzed on day 18 displayed no significant differences when compared with vehicle-treated rats (Table 2 ). In contrast, recipients of spleen cells from rrSCF64-treated rats analyzed either on day 27, 28, or 29 showed significantly (p<0.05) higher regeneration capacity than spleen cells from donors treated similarly with vehicle (Table 3, Table 4 , and In an additional series of experiments, rats were treated separately with either rat albumin (conjugated with PEG), rrSCF 164 or rhGCSF for 7 days and spleen cells from each of these donors were assayed for thymocyte progenitor activity. Rats treated with albumin conjugated with PEG were similar to vehicle-treated rats in that no peripheral blood, spleen, or bone marrow hematological changes were observed (data not shown). Furthermore, no change was noted in the ability of splenocytes from PEG-conjugated albumintreated rats to cause donor-origin thymus regeneration when compared with vehicle-treated spleen cells from several separate experiments Our data indicate that elevated levels of donororigin thymocytes due to spleen-cell transplants were most evident on days 27-28 posttransplantation. This is in contrast to the kinetics of regeneration by bone marrow progenitors that reach plateau levels of regeneration by day 20 (Greiner et al., 1984 (Andrews et al., 1990; McNiece et al., 1991a McNiece et al., , 1991b Migliaccio et al., 1991; Billips et al., 1992; Bodine et al., 1992) . Moreover, SCF has been shown to stimulate the in vitro growth of enriched marrow-derived stem-cell populations (Bernstein et al., 1991; de Vries et al., 1991; Williams et al., 1992 Agus et al., 1991 (Fowlkes and Pardell, 1989; Spangrude and Scollay, 1990) . Furthermore, in vitro (Deluca, 1986; Deluca and Misel, 1986) and in vivo Komschlies et al., 1987; Hayes et al., 1992) thymic repopulation studies have suggested that this accessory cell may be a rate-limiting factor in thymocyte repopulation.
Thus, rrSCF TM may affect a myeloid accessory cell, rather than a lymphoid progenitor cell, resulting in increased accessory cell activity and enhanced thymocyte repopulation.
Although thymocyte progenitor activity has been identified in many tissues throughout the body , the primary source, or at least the source with the largest population, is the bone marrow in the adult (Kadish and Basch, 1986; Greiner et al., 1984; Goldschneider et al., 1986; Katsura et al., 1986) . However, we have observed that the primary site of rrSCF TM action on this type of cell activity is selective to the spleen, an apparently secondary source of thymocyte progenitor activity in the rat (Greiner et al., 1984; Goldschneider et al., 1986 Abramson et al. (1977) were the first to demonstrate that T-restricted stem progenitor cells may exist in the bone marrow using radiation-induced chromosomal aberrations as a clonal marker. Dick et al. (1985) detected similar cells using insertion of a selectable gene as a clonal marker. Moreover, it is certain that pluripotent hemopoietic stem cells are able to reconstitute all blood lineages including T cells that are generated in the thymus (Jordan et al., 1990) . Indeed, certain studies have suggested that prethymic-origin thymus repopulating cells may be separated into two distinct cell phenotypes in the mouse (Spangrude et al., 1989 
MATERIALS AND METHODS

Growth Factors
Recombinant rrSCF TM and rhG-CSF were purified after expression in Escherichia coli, as described previously (Souza et al., 1986; Langley et al., 1992) . Methoxypolyethylene glycol (MW=6000) was obtained from Union Carbide Chemicals and Plastic Company (South Charleston, WV) and activated as previously described (Veronese et al., 1989) . PEG-conjugated SCF, containing two to three PEG strands per SCF subunit, was prepared by an adaptation of a previously published method (Tanaka et al., 1991) and used because previous studies have shown that PEG improves the stability of other cytokines in vivo (Katre et al., 1986; Tanaka et al., 1991 22, 1992) (Accepted August 31, 1992) 
